Breast Cancer: New Horizons, Current Controversies – Comprehensive Educational Curriculum

This comprehensive educational curriculum encompasses the full range of breast cancer care, covering topics such as mechanisms of disease, improvements in diagnostic methods, treatment innovations, and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence, and clinical skills of healthcare professionals specializing in oncology.

Target Audience

This curriculum is well-suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses; and other clinicians involved in the care of breast cancer patients.

Learning Objectives

• Apply knowledge of recent clinical data together with current expert recommendations to patient selection for new and emerging therapies for advanced breast cancer.
• Apply knowledge in the treatment of breast cancer in special populations (including the elderly and young women) and adjust treatment decisions for specific patients as needed.
• Select appropriate risk assessment modalities, where applicable, and make evidence-based therapeutic selections for women who are candidates for neoadjuvant or adjuvant therapy and know the limitations of genomic testing.
• Apply recent clinical data and expert recommendations to the management of women with breast cancer who are treated with mastectomy, including integration of surgical methods, breast reconstruction options, and post-mastectomy radiation if needed.
• Assess current practices with regard to symptom management during active treatment and in survivorship and consider the needs for fertility and lifestyle counseling among patients with breast cancer and survivors, and improve current practices if needed.
• Evaluate the genetic and personal risk factors of breast cancer and utilize appropriate genetic testing for hereditary breast cancer.

Agenda

Thursday, July 20, 2023

• Welcoming Remarks – Harold Burstein, MD, PhD
• SESSION I: BREAST SURGERY
  • Management of the Axilla – Monica Morrow, MD
  • Reconstruction Options in 2023 – Matthew Carty, MD
  • Lymphatic Surgery – Michelle Coriddi, MD
  • Q&A
  • Lecture: The Future of Breast Cancer Pathology – Jorge Reis-Filho, MD, PhD, FRCPath
• SESSION II: GENETICS
  • Prophylactic Surgery: Who, What, When? – Barbara Smith, MD, PhD
  • Genetic Testing: Who, Which Test, When? – Judy Garber, MD, MPH
  • Managing Hereditary Breast Cancer: What We Do; What We Still Don’t Know – Nadine Tung, MD
  • Q&A
• Lunch Break
• SESSION III: RADIATION THERAPY
  • Schedules and Regimens – Jennifer Bellon, MD
  • Postmastectomy Radiation – Rachel Jimenez, MD
  • Oligometastatic Disease – Steven Chmura, MD, PhD
  • Radiotherapy Options for Brain Metastases – Ayal Aizer, MD, MHS
  • Q&A
  • Lecture: The Future of Breast Cancer: Radiation Oncology – Bruce Haffty, MD, MS
• Tumor Board: Local Regional Therapy – Tari King, MD, FACSFriday

Friday, July 21, 2023

• SESSION IV: ER POSITIVE BREAST CANCER
  • Novel Agents: SERDs – Rinath Jeselsohn, MD
  • Novel Agents: AKT Pathways – Alex Toker, PhD
  • Male Breast Cancer – Jose Pablo Leone, MD
  • Role of ADCs in ER+ Breast Cancer – Paolo Tarantino, MD
  • Special Considerations in Premenopausal Women – Erica Mayer, MD, MPH
  • Break
  • Adjuvant Endocrine Therapy: How Long? – Heather Parsons, MD, MPH
  • Adjuvant Therapy: CDK4/6 Inhibitors – Sarah Sammons, MD
  • Adjuvant Therapy: Chemotherapy – Beverly Moy, MD, MPH
  • Local Regional Considerations in Older Cancer Patients – Christina Minami, MD
  • Q&A
  • Lecture: The Future of Breast Cancer Clinical Trials Designs – Nabihah Tayob, PhD
• Tumor Board: Advanced Breast Cancer – Erica Mayer, MD, MPH

Saturday, July 22, 2023

• Tumor Board: Early Stage Breast Cancer – Hal Burstein, MD, PhD
• ASCO Highlights – Harold Burstein, MD, PhD
• SESSION VII: HER2 POSITIVE BREAST CANCER
  • ADCs for HER2 Positive Tumors – Rachel Occhiogrosso Abelman, MD
  • HER2 Testing – Laura Collins, MD
  • Treatment for Early-Stage HER2 Positive Breast Cancer – Adrienne Waks, MD
  • Curing HER2+ Breast Cancer – Steven Isakoff, MD, PhD
  • Q&A
• Closing Remarks – Harold Burstein, MD, PhD